IP Library Granted Patent US 11,255,860
Granted Patent B2
US 11,255,860 · App. 15/881,489 · Granted Feb 22, 2022

Glucose sensor

Inventors: Barry Colin Crane (Oxfordshire, GB); William Paul Paterson (Oxfordshire, GB); Nicholas Paul Barwell (Oxfordshire, GB); Peter Edgley (Oxfordshire, GB)
Assignees: Baxter International Inc.; Baxter Healthcare SA
G01N33/66A61B5/1459A61B5/1473A61B5/14532G01N21/6428G01N21/7703G01N21/6408G01N27/3271G01N2021/6432G01N2021/6434G01N2021/6441G01N2021/6484G01N2021/772G01N2021/773G01N2021/7786G01N2021/7793
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,255,860
App. No.
15/881,489
Granted
Feb 22, 2022
Kind
B2
Abstract

A method of quantifying the amount of glucose in a sample is provided herein that may further comprise an interferent such as mannitol. At least two measurements are obtained using measurement methods that differ in their sensitivity to the amount of interferent in the sample, thus enabling the results to be compared to determine whether any interferent is present in the sample. A glucose sensor for carrying out a method described herein is also provided.

Claims (37)

1. A method of determining whether an interferent is present in a glucose-containing sample that may further comprise the interferent and quantifying the amount of glucose, the method comprising:

(i) providing incident light to a sensing region of a glucose sensor exposed to the glucose-containing sample, wherein the glucose sensor comprises:

the sensing region comprising at least a first indicator system comprising a first receptor for binding to glucose and a first fluorophore associated with the first receptor; a second indicator system comprising a second receptor for binding to glucose and a second fluorophore associated with the second receptor; a polymeric matrix, wherein the first receptor and first fluorophore and the second receptor and second fluorophore are bound to the polymeric matrix such that the polymeric matrix simultaneously carries the first receptor and first fluorophore together with the second receptor and second fluorophore; and

an optical waveguide for directing light onto the sensing region;

(ii) obtaining a first measurement of the amount of glucose by a first measurement method comprising detecting the emission of the first fluorophore;

(iii) obtaining a second measurement of the amount of glucose by a second measurement method comprising detecting the emission of the second fluorophore, wherein the second measurement method differs in its sensitivity to the amount of the interferent in the sample from the first measurement method; and

(iv) comparing the first measurement and the second measurement and thereby determining whether any of the interferent is present in the sample;

wherein the interferent is a substance that is capable of interfering with the binding of glucose to the first receptor,

wherein once the interferent is determined to be present in the glucose-containing sample, the method further comprising:

(v) allowing a sufficient time delay for any of the interferent present in the glucose-containing sample to substantially clear the sample; and

(vi) providing incident light to the sensing region of the glucose sensor and detecting the emission of the first fluorophore, thereby obtaining a third measurement of the amount of glucose in the sample, the third measurement having substantially no or a reduced contribution from the interferent.

2. The method according to claim 1 , wherein the first receptor has an association constant K G1 with glucose and an association constant K M1 with the interferent, and

wherein the second receptor has an association constant K G2 with glucose and an association constant K M2 with the interferent, and wherein K G2 /K M2 is different from K G1 /K M1 .

3. The method according to claim 1 , wherein the first measurement and the second measurement are obtained in a single emission detection step.

4. The method according to claim 1 , wherein the first fluorophore and the second fluorophore have peak emission wavelengths that differ by at least 5 nm.

5. The method according to claim 2 , wherein [K G2 /K M2 ]/[K G1 /K M1 ] is greater than 2 or less than 0.5.

6. The method according to claim 2 , wherein the first receptor and the second receptor are boronic acid receptors.

7. The method according to claim 6 , wherein the first receptor contains two boronic acid groups and said second receptor contains one boronic acid group.

8. The method according to claim 1 , wherein the sample that may further comprise an interferent is an in vivo sample.

9. The method according to claim 1 , wherein the sample that may further comprise an interferent is an in vivo sample and wherein the method comprises:

(vii) obtaining the first measurement at a time point t test ;

(viii) obtaining a fourth measurement by a fourth measurement method, wherein the fourth measurement method comprises electrochemically measuring the amount of glucose, or of the interferent, in the sample at the time point t test ; and

(viiii) comparing the first measurement and the fourth measurement, thereby determining whether the first measurement contains a contribution from the interferent in the sample.

10. The method according to claim 9 , wherein the method is carried out on a human or animal subject and the sample is an in vivo bodily fluid of the subject, and wherein step (vii) comprises carrying out an in vivo measurement on the bodily fluid at the time t test , and wherein step (viii) comprises extracting a portion of the bodily fluid from the subject at the time t test and carrying out an in vitro electrochemical measurement thereon.

11. The method according to claim 9 , wherein the method comprises carrying out the sequence of steps (vii) to (viiii) one or more times, each at different time points, until in the step (viiii) of comparing the first measurement and the second measurement it is determined that the first measurement contains substantially no or a reduced contribution from the interferent.

12. The method according to claim 9 , wherein in the step (viiii) of comparing the first measurement and the fourth measurement an estimate of the amount of the interferent in the sample at the time point t test is obtained and wherein the method further comprises:

(iv) allowing a sufficient time delay for any of the interferent present in the sample at test to substantially clear the sample; and

(v) providing incident light to the sensing region of the sensor and detecting the emission of the first fluorophore, thereby obtaining a fifth measurement of the amount of glucose in the sample, the fifth measurement having substantially no or a reduced contribution from the interferent.

13. The method according to claim 1 , wherein the interferent is selected from the group consisting of (a) an interferent that comprises a cis-diol group and (b) an amine.

14. The method according to claim 13 , wherein the interferent that comprises a cis-diol group is selected from the group consisting of a sugar alcohol and a saccharide.

15. The method according to claim 1 , wherein the interferent is selected from the group consisting of mannitol, sorbitol, galactitol, inositol, fructose, galactose, arabinose, glutamine and catechol amines.

16. A glucose sensor for quantifying and performing the method of claim 2 ,

wherein said first receptor has an association constant Km with glucose and an association constant KM1 with said interferent, and

wherein said second receptor has an association constant K G2 with glucose and an association constant K M2 with said interferent, and wherein K G2 /K M2 is different from K G1 /K M1 .

17. The method according to claim 1 , wherein the method further comprises calculating the concentration of glucose in the sample.

18. The method according to claim 1 , wherein the method further comprises correcting for the presence of any of the interferent in the sample.

19. The method according to claim 1 , wherein the first receptor and second receptor are boronic acid receptors or comprise one or more groups of formula H 3 AsO 3 , H 2 AsO 3 —, H 6 TeO 6 , H 5 TeO 6 —, Ge(OH) 6 or GeO(OH) 3 —, or derivatives thereof.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2025
From: BAXTER INTERNATIONAL INC.
To: VANTIVE US HEALTHCARE LLC
Reel/Frame 074042/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2025
From: BAXTER HEALTHCARE SA
To: VANTIVE HEALTH GMBH
Reel/Frame 074046/0139 →
SECURITY INTEREST Recorded Jan 31, 2025
From: VANTIVE US HEALTHCARE LLC; GAMBRO RENAL PRODUCTS, INC.
To: ARES CAPITAL CORPORATION
Reel/Frame 070076/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2019
From: CRANE, BARRY COLIN; PATERSON, WILLIAM; BARWELL, NICHOLAS PAUL; EDGLEY, PETER
To: LIGHTSHIP MEDICAL LIMITED
Reel/Frame 048821/0845 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2019
From: LIGHTSHIP MEDICAL LIMITED
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 048822/0461 →
Continuity (3)
Continuation 13686760 · Nov 27, 2012
Provisional Application 61662560 · Jun 21, 2012
Related Publication 20180306802A1 · Oct 25, 2018